Skov T - Search Results

1

A phase II trial of the vitamin D analogue Seocalcitol (EB1089) in patients with inoperable pancreatic cancer.

Evans TR, Colston KW, Lofts FJ, Cunningham D, Anthoney DA, Gogas H, de Bono JS, Hamberg KJ, Skov T, Mansi JL. Evans TR, et al. Among authors: skov t. Br J Cancer. 2002 Mar 4;86(5):680-5. doi: 10.1038/sj.bjc.6600162. Br J Cancer. 2002. PMID: 11875725 Free PMC article. Clinical Trial.

2

A phase II study of the vitamin D analogue Seocalcitol in patients with inoperable hepatocellular carcinoma.

Dalhoff K, Dancey J, Astrup L, Skovsgaard T, Hamberg KJ, Lofts FJ, Rosmorduc O, Erlinger S, Bach Hansen J, Steward WP, Skov T, Burcharth F, Evans TR. Dalhoff K, et al. Among authors: skov t. Br J Cancer. 2003 Jul 21;89(2):252-7. doi: 10.1038/sj.bjc.6601104. Br J Cancer. 2003. PMID: 12865912 Free PMC article. Clinical Trial.

3

A Phase I study of CHS 828 in patients with solid tumor malignancy.

Hovstadius P, Larsson R, Jonsson E, Skov T, Kissmeyer AM, Krasilnikoff K, Bergh J, Karlsson MO, Lönnebo A, Ahlgren J. Hovstadius P, et al. Among authors: skov t. Clin Cancer Res. 2002 Sep;8(9):2843-50. Clin Cancer Res. 2002. PMID: 12231525 Clinical Trial.

4

CHS 828, a novel pyridyl cyanoguanidine with potent antitumor activity in vitro and in vivo.

Hjarnaa PJ, Jonsson E, Latini S, Dhar S, Larsson R, Bramm E, Skov T, Binderup L. Hjarnaa PJ, et al. Among authors: skov t. Cancer Res. 1999 Nov 15;59(22):5751-7. Cancer Res. 1999. PMID: 10582695

5

Different impact of excision repair cross-complementation group 1 on survival in male and female patients with inoperable non-small-cell lung cancer treated with carboplatin and gemcitabine.

Holm B, Mellemgaard A, Skov T, Skov BG. Holm B, et al. Among authors: skov bg, skov t. J Clin Oncol. 2009 Sep 10;27(26):4254-9. doi: 10.1200/JCO.2008.18.8631. Epub 2009 Aug 10. J Clin Oncol. 2009. PMID: 19667277

6

Phase IV head-to-head randomized controlled trial comparing ingenol mebutate 0·015% gel with diclofenac sodium 3% gel for the treatment of actinic keratosis on the face or scalp.

Stockfleth E, Harwood CA, Serra-Guillén C, Larsson T, Østerdal ML, Skov T. Stockfleth E, et al. Among authors: skov t. Br J Dermatol. 2018 Feb;178(2):433-442. doi: 10.1111/bjd.16048. Epub 2018 Jan 15. Br J Dermatol. 2018. PMID: 29030864 Clinical Trial.

7

ERCC1 and Ki67 in small cell lung carcinoma and other neuroendocrine tumors of the lung: distribution and impact on survival.

Skov BG, Holm B, Erreboe A, Skov T, Mellemgaard A. Skov BG, et al. Among authors: skov t. J Thorac Oncol. 2010 Apr;5(4):453-9. doi: 10.1097/JTO.0b013e3181ca063b. J Thorac Oncol. 2010. PMID: 20104194 Free article.

8

Reclassification of neuroendocrine tumors improves the separation of carcinoids and the prediction of survival.

Skov BG, Krasnik M, Lantuejoul S, Skov T, Brambilla E. Skov BG, et al. Among authors: skov t. J Thorac Oncol. 2008 Dec;3(12):1410-5. doi: 10.1097/JTO.0b013e31818e0dd4. J Thorac Oncol. 2008. PMID: 19057265 Free article.

9

The prevalence of EGFR mutations in non-small cell lung cancer in an unselected Caucasian population.

Skov BG, Høgdall E, Clementsen P, Krasnik M, Larsen KR, Sørensen JB, Skov T, Mellemgaard A. Skov BG, et al. Among authors: skov t. APMIS. 2015 Feb;123(2):108-15. doi: 10.1111/apm.12328. Epub 2014 Nov 25. APMIS. 2015. PMID: 25421919

10

The prevalence of programmed death ligand-1 (PD-L1) expression in non-small cell lung cancer in an unselected, consecutive population.

Skov BG, Rørvig SB, Jensen THL, Skov T. Skov BG, et al. Among authors: skov t. Mod Pathol. 2020 Jan;33(1):109-117. doi: 10.1038/s41379-019-0339-0. Epub 2019 Aug 5. Mod Pathol. 2020. PMID: 31383957 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

106 results

Search Page

Filters